HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study

E. L. M. Barr · A. J. Cameron · B. Balkau · P. Z. Zimmet · T. A. Welborn · A. M. Tonkin · J. E. Shaw

Received: 2 June 2009 / Accepted: 24 September 2009 © Springer-Verlag 2009

Abstract
Aims/hypothesis We assessed whether the relationships between insulin sensitivity and all-cause mortality as well as fatal or non-fatal cardiovascular disease (CVD) events are independent of elevated blood glucose, high blood pressure, dyslipidaemia and body composition in individuals without diagnosed diabetes.

Methods Between 1999 and 2000, baseline fasting insulin, glucose and lipids, 2 h plasma glucose, HbA1c, anthropometrics, blood pressure, medication use, smoking and history of CVD were collected from 8,533 adults aged >35 years from the population-based Australian Diabetes, Obesity and Lifestyle study. Insulin sensitivity was estimated by HOMA of insulin sensitivity (HOMA-%S). Deaths and fatal or non-fatal CVD events were ascertained through linkage to the National Death Index and medical records adjudication.

Results After a median of 5.0 years there were 277 deaths and 225 CVD events. HOMA-%S was not associated with all-cause mortality. Compared with the most insulin-sensitive quintile, the combined fatal or non-fatal CVD HR (95% CI) for quintiles of decreasing HOMA-%S were 1.1 (0.6–1.9), 1.4 (0.9–2.3), 1.6 (1.0–2.5) and 2.0 (1.3–3.1), adjusting for age and sex. Smoking, CVD history, hypertension, lipid-lowering medication, total cholesterol and waist-to-hip ratio moderately attenuated this relationship. However, the association was rendered non-significant by adding HDL. Fasting plasma glucose, but not HOMA-%S significantly improved the prediction of CVD, beyond that seen with other risk factors.

Conclusions/interpretation In this cohort, HOMA-%S showed no association with all-cause mortality and only a modest association with CVD events, largely explained by its association with HDL. Fasting plasma glucose was a better predictor of CVD than HOMA-%S.

Keywords Cardiovascular diseases · Hyperglycaemia · Insulin sensitivity and resistance · Metabolic syndrome · Mortality

Abbreviations
AusDiab Australian Diabetes, Obesity and Lifestyle
CVD Cardiovascular disease
FPG Fasting plasma glucose
HOMA-IR  HOMA of insulin resistance  
HOMA-%S  HOMA of insulin sensitivity  
2hPG  2 h plasma glucose  
NDI  National Death Index  
PTCA  Percutaneous transluminal coronary artery angioplasty

**Introduction**

Insulin resistance precedes the development of hyperglycaemia and subsequent diabetes [1], which are both considered to be risk factors for the development of cardiovascular disease (CVD) and premature mortality [2–4]. Exploring the relative associations of hyperglycaemia and insulin resistance (or its reciprocal, insulin sensitivity) among persons without diagnosed diabetes may help elucidate possible mechanisms underlying premature mortality and CVD in the general population. Furthermore, as there is evidence of considerable heterogeneity in insulin resistance among individuals with different degrees of glucose tolerance [5], it is important to ascertain whether the presence of hyperglycaemia and insulin resistance can help identify high-risk groups.

In addition to hyperglycaemia, insulin resistance is also associated with several other CVD risk factors, including adiposity, dyslipidaemia and hypertension [6], which are collectively identified as the metabolic syndrome [7]. However, uncertainty remains as to whether insulin resistance is itself an independent risk factor for premature mortality and CVD. Although the euglycaemic–hyperinsulinaemic clamp is considered the gold standard method for measuring insulin resistance [8], few large studies have used it to evaluate the association between insulin resistance and CVD [9–11], as it is invasive and time-consuming. Consequently, surrogate markers of insulin resistance have been developed.

The simplest of these is plasma insulin, with two meta-analyses reporting a weak but statistically significant association between hyperinsulinaemia and CVD [12, 13]. However, one of these analyses combined results from several studies that did not adequately adjust for all components of the metabolic syndrome [12], while the other potentially introduced measurement error by combining individual level data from studies that had used different protocols and insulin assays (some specific and others not specific for insulin) [13].

Other markers of insulin resistance are based on both plasma glucose and insulin [14, 15]. The HOMA of insulin resistance (HOMA-IR) [16] and HOMA of insulin sensitivity (HOMA-%S) [17] are commonly used to estimate insulin resistance and sensitivity, respectively. These models were developed from human and animal experimental data, with the updated HOMA-%S computer model being more accurate than the original HOMA-IR model [17]. Several [18–21], but not all [22–24] large prospective population-based studies have found HOMA-IR values to be significantly associated with incident CVD, while the HOMA-%S model values have been found to be associated with CVD in older women [25].

The Australian Diabetes, Obesity and Lifestyle (AusDiab) study is a national, prospective, population-based study of adult men and women, and represents the largest single study to assess the relationship between HOMA-%S and CVD after adjusting for components of the metabolic syndrome, including blood glucose and other important CVD risk factors. In this study, we used insulin data from 8,533 men and women without diagnosed diabetes, as assessed with an insulinspecific assay, to investigate: (1) the associations between HOMA-%S and both 5 year all-cause mortality rates and combined fatal or non-fatal CVD events; and (2) whether these relationships were independent of elevated blood glucose, high blood pressure, dyslipidaemia and body composition.

**Methods**

**Study design** The AusDiab study includes 11,247 men and women aged ≥25 years. Methods and response rates are reported elsewhere [26, 27]. Between 1999 and 2000, a stratified clustered sample was drawn from 42 randomly selected census districts, six in each of the states and in the Northern Territory of Australia. The sampling frame consisted of 17,129 eligible households, from which 20,347 individuals completed a household interview. Of these, 11,247 (55%) attended a biomedical examination, yielding an estimated response rate at baseline of 37%. A 5 year follow-up study that included the assessment of non-fatal CVD outcomes was undertaken between 2004 and 2005, and of the 10,788 eligible individuals, 8,802 (82%) completed a questionnaire including history of CVD events. The Ethics Committees of the International Diabetes Institute, Monash University, the Australian Institute of Health and Welfare and the Sir Charles Gairdner Hospital, Western Australia approved the study, and informed consent was obtained from participants.

**Baseline measures** Baseline data on age, sex, use of anti-hypertensive and lipid-lowering medications, and history of both CVD (angina, myocardial infarction or stroke) and smoking were collected by interviewer-administered questionnaires. Measurements included blood pressure [28], anthropometrics [29] and a fasting (≥9 h) blood sample. All participants, excluding pregnant women and people taking hypoglycaemic medication, underwent a 75 g OGTT. Fasting plasma insulin, fasting plasma glucose (FPG), 2 h plasma glucose (2hPG) and fasting serum total cholesterol,
triacylglycerol and HDL were measured using an analyser (AU600; Olympus Optical, Tokyo, Japan). Glycated haemoglobin was measured from frozen samples of whole blood collected in EDTA tubes and stored at −70°C for 2 to 36 months, using high-performance liquid chromatography (Bio-Rad Variant; Bio-Rad, Hercules, CA, USA) with standardised conversion to HbA1c (normal range 4.2–6.3%). Serum samples for insulin were stored at −80°C until assayed. Serum insulin was measured using a human insulin-specific radioimmunoassay kit (Linco Research, St Charles, MO, USA). Insulin assays were only conducted in participants aged >35 years. All specimens were analysed at a central laboratory. Insulin sensitivity was estimated from FPG and fasting insulin concentrations using HOMA. HOMA-%S was calculated with the HOMA-2 program [17].

Outcome measures Mortality status and both underlying and contributory causes of death were ascertained by linking all participants to the Australian National Death Index (NDI) [4]. People not matched to the NDI were assumed to be alive. The accuracy of the NDI for ascertainment of CVD deaths and vital status has been previously established [30]. Deaths were attributed to CVD if the underlying cause of death was coded I10–I25, I46.1, I48, I50–I199 or R96 according to the 2006 International Classification of Diseases 10th revision (www.who.int/classifications/icd/en/, accessed 6 January 2009). In addition, participants with uncomplicated diabetes (E109, E119 or E149) or unspecified hyperlipidaemia (E785) as an underlying cause of death on the death certificate were attributed a CVD death (n=3) if any of the CVD codes (I10–I25, I46.1, I48, I50–I199 or R96) were recorded in the first position on the death certificate.

During the 5 year follow-up study, 8,802 participants answered an interview-administered questionnaire on CVD events, including myocardial infarction, stroke, percutaneous transluminal coronary artery angioplasty (PTCA) and coronary artery bypass graft surgery. Self-reported CVD events that occurred between baseline and follow-up were adjudicated by two physicians (J. E. Shaw [diabetologist], A. M. Tonkin [cardiologist]) using medical records. This method has been validated against a state-wide hospital morbidity database [31]. A composite CVD outcome was defined as fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, PTCA, coronary artery bypass graft or other deaths associated with CVD.

Participants were excluded if at baseline they: (1) were aged <35 years (n=1,603); (2) had known diabetes (n=470) based on self-reported physician-diagnosed diabetes with use of hypoglycaemic medication or FPG⩾7.0 mmol/l or 2hPG⩾11.1 mmol/l; (3) had not fasted for ⩾9 h (n=16); (4) were pregnant (n=17); (5) had FPG or 2hPG values <2.5 mmol/l (n=37); and (6) had missing HOMA-%S values (n=40) or missing values for other covariates (n=527). Four participants who died but could not be matched to the NDI were excluded. Furthermore, 1,591 participants could not be included in the follow-up for fatal or non-fatal CVD events, as they did not complete the 2004–2005 non-fatal CVD questionnaire. Thus, for all-cause mortality the analyses were undertaken in 8,533 participants and for fatal or non-fatal CVD follow-up the analyses were based on 6,942 participants.

The follow-up period for all-cause mortality extended to the date of death or 7 April 2006, whichever came first. Follow-up of the composite fatal or non-fatal CVD events lasted until the date of event or death, or the individual’s 2004–2005 testing date (between June 9, 2004 and April 7, 2006), whichever occurred first. CVD follow-up analyses were based on the first CVD event to occur after baseline testing. For people who died from CVD, non-fatal CVD events could not be obtained and therefore their CVD death was considered the CVD endpoint.

Statistical analysis To fully assess the relationship between HOMA-%S and both all-cause mortality and CVD events, HOMA-%S was analysed as a continuous and categorical variable. For the continuous analysis, HOMA-%S had a positively skewed distribution and was log-transformed. Categories were based on quintiles of HOMA-%S and were determined separately for all-cause mortality and CVD events follow-up. The first quintile represented individuals with the highest insulin sensitivity and the fifth quintile represented those with the lowest insulin sensitivity. Unadjusted mortality rates (95% CI) per 1,000 person-years were calculated for each quintile of HOMA-%S. To test differences in means and proportions for baseline characteristics between the quintiles of HOMA-%S, one-way analysis of variance and χ² tests were used, respectively. FPG, 2hPG and triacylglycerol were not normally distributed and were logarithmically transformed prior to analysis.

Cox proportional hazards regression was used to examine the unadjusted and adjusted association between HOMA-%S and both all-cause mortality and CVD events (fatal or non-fatal). A linear or non-linear relationship between HOMA-%S and each of the outcomes was tested by calculating the likelihood ratio tests of a Cox model adjusted for age and sex, with and without the squared term for HOMA-%S. Multivariate models were adjusted for age, sex, previous history of CVD (yes or no), smoking (never, ex-smoker or current smoker), hypertension (blood pressure ≥140/90 mmHg or self-reported antihypertensive medication use, or blood pressure <140/90 mmHg and no medication use), systolic and diastolic blood pressure, total cholesterol, HDL, non-HDL (total cholesterol minus HDL), triacylglycerol, self-reported lipid-lowering medication use (yes or no), waist-to-hip ratio, waist circumference and BMI (kg/m²). Age, systolic and
diastolic blood pressure, total cholesterol, HDL, non-HDL, triacylglycerol, waist-to-hip ratio, waist circumference and BMI were modelled as continuous variables. The influence of CVD risk factors on the relationship between HOMA-%S and both all-cause mortality and CVD events was evaluated by: (1) entering each covariate individually after adjusting for age and sex to assess the impact of hypertension, dyslipidaemia, obesity and hyperglycaemia; and (2) building multivariate models to assess the combined effects of key covariates. Also, to assess whether the relationships between HOMA-%S and the outcome measures were independent of plasma glucose, HOMA-%S was modelled with FPG, 2hPG and HbA1c, adjusting for age, sex and the CVD covariates listed above. The predictive ability of HOMA-%S was compared with FPG, 2hPG and HbA1c using log-likelihood ratio statistics, where a model containing HOMA-%S, age, sex and CVD covariates was nested within models also containing FPG, 2hPG or HbA1c. For these models, 2hPG and HbA1c were modelled as linear variables and FPG was modelled as a linear spline with one knot at 5.1 mmol/l, as this functional form of FPG best describes the J-shaped relationship previously reported for FPG and CVD events [32].

Interactions between quintiles of HOMA-%S and sex, age (<65 and ≥65 years), previous history of CVD (no or yes), categories of abnormal glucose metabolism (normal glucose tolerance or impaired fasting glucose, impaired glucose tolerance or newly diagnosed diabetes), BMI (<25 or ≥25 to <30 or ≥30 kg/m²) and waist-to-hip ratio (men: ≤0.95 or >0.95, women: ≤0.80 or >0.80) were tested by using log-likelihood ratio tests of models containing the variables as single terms nested within models including the first-order interactions. Interactions were considered significant at \( p < 0.01 \).

All analyses were repeated using: (1) fasting insulin (pmol/l) as the surrogate measure of insulin sensitivity instead of HOMA-%S; (2) a cohort that excluded individuals with newly diagnosed diabetes at baseline; and (3) a cohort that excluded individuals with self-reported myocardial infarction or stroke at baseline. Multi-collinearity between covariates was tested with the variance inflation factor, which was found to be <3 for all independent variables [33]. Proportional hazards assumptions were satisfied as assessed with graphs of log-log plots of the relative hazards by time for discrete variables and by scaled Schoenfeld residuals. Analyses were conducted with Stata Statistical Software version 9.2 (StataCorp, College Station, TX, USA).

### Results

For the total cohort of 8,533 individuals the mean (range) age was 54 (36–91) years, 4,700 (55%) were women and 7,448 (87%) reported being born in Australia, New Zealand or the UK. In unadjusted analyses (Table 1), declining insulin sensitivity, as measured by HOMA-%S, was significantly associated with other risk factors for premature mortality and CVD events.

There were 277 deaths (117 in women) after a median (interquartile range) of 5.0 (0.5) years and 225 fatal or non-fatal CVD events after a median (interquartile range) of 5.0 (0.2) years. Of these events, 74 were in women, 69 were fatal or non-fatal myocardial infarctions, 45 were fatal or non-fatal strokes, 45 were PTCAs and 35 were coronary artery bypass grafts; 31 were deaths due to other types of atherosclerotic CVD.

In unadjusted analyses, there was no relationship between HOMA-%S and all-cause mortality (Fig. 1a). For CVD a linear association with HOMA-%S was observed (Fig. 1b). Prediction of CVD was not improved by adding a squared term for HOMA-%S \( (p > 0.5 \) in log-likelihood ratio test).

For all-cause mortality, no association was observed with quintiles of declining insulin sensitivity in either unadjusted (quintile HR [95% CI]: 1.2 [0.8–1.8], 1.4 [1.0–2.1], 1.2 [0.8–1.8] and 1.3 [0.9–1.9]) or age- and sex-adjusted (quintile HR [95% CI]: 1.1 [0.8–1.7], 1.0 [0.7–1.5], 0.9 [0.6–1.4] and 1.1 [0.7–1.6]) models. After adjustment for other covariates and re-analysing HOMA-%S as a continuous variable, there was still no relationship with all-cause mortality (data not shown). Age, sex, waist-to-hip ratio, history of CVD and abnormal glucose tolerance status did not significantly modify the relationship between HOMA-%S and all-cause mortality \( (all \ p > 0.03 \)).

In unadjusted analysis, individuals in the least insulin-sensitive quintile of HOMA-%S were more than twice as likely to experience a CVD event than those in the most insulin-sensitive quintile (Table 2). Adjustment for age, sex, glucose and other metabolic covariates only moderately influenced this relationship (Tables 2 and 3). Marked attenuation between HOMA-%S and CVD was observed after adjusting for HDL \( (p = 0.04 \) for trend, age- and sex-adjusted [Table 2]; \( p = 0.14 \) for trend, multivariate-adjusted [Table 3]).

Similar results were found when HOMA-%S was modelled as a continuous variable. The fatal or non-fatal CVD HRs (95% CI, \( p \)) per SD decrease of log-HOMA-%S were 1.36 (1.20–1.54, \( p < 0.01 \)) in an unadjusted model and 1.30 (1.14–1.49, \( p < 0.01 \)) after adjusting for age and sex. Although attenuated, the relationship remained significant after adjusting for previous history of CVD, smoking, hypertension (blood pressure ≥140/90 mmHg or self-reported antihypertensive medication use), total cholesterol, self-reported lipid-lowering medication use and waist-to-hip ratio (1.24 [1.08–1.43, \( p < 0.01 \)). However, the relationship became non-significant after further adjustment for HDL (1.15 [1.00–1.34, \( p = 0.06 \)).

FPG \( (p < 0.01 \), but not 2hPG \( (p = 0.43 \) or HbA1c \( p = 0.13 \) significantly improved the prediction of CVD after adjusting
for HOMA-%S and the covariates (Table 4). Adding quintiles of HOMA-%S to multivariate models with FPG, 2hPG or HbA1c did not improve the prediction of CVD ($p > 0.6$ for all). Multivariate models including HOMA-%S and plasma glucose measures showed that the association between CVD and FPG was of borderline significance ($HR = 3.6$ [95% CI 1.5–8.5, $p = 0.01$] per SD [0.7 mmol/l] decrease for FPG<5.1 mmol/l and $1.0 \times 1.2$, $p = 0.05$] per SD increase for FPG ≥5.1 mmol/l), whereas 2hPG and HbA1c were not significantly associated with CVD when modelled with HOMA-%S ($HR = 1.0$ [95% CI 0.9–1.2, $p = 0.42$] per SD [2.2 mmol/l] increase for 2hPG; $HR = 1.1$ [95% CI 1.0–1.2, $p = 0.10$] per SD [0.4%] increase for HbA1c).

No significant interactions were observed between HOMA-%S (in quintiles) and age, sex, BMI, waist-to-hip ratio, history of CVD or abnormal glucose tolerance status for CVD (all $p > 0.05$). For individuals without a self-reported history of myocardial infarction or stroke at baseline (n=6,590), the HRs (95% CI) for quintiles of decreasing HOMA-%S were 0.8 (0.4–1.4), 1.2 (0.7–2.1),

![Fig. 1 Unadjusted rates per 1,000 person-years for all-cause mortality (a) and fatal or non-fatal CVD events (b) according to quintiles of decreasing HOMA-%S in individuals without diagnosed diabetes: the AusDiab study. y-axes in log_{10} scale](image-url)
broad range of CVD risk factors, including previous history and both CVD and all-cause mortality, after accounting for a women we examined the relationship between HOMA-%S.

In this population-based prospective study of men and women we examined the relationship between HOMA-%S and both CVD and all-cause mortality, after accounting for a broad range of CVD risk factors, including previous history of CVD, smoking, hypertension, total cholesterol, lipid-lowering medication use, dyslipidaemia and obesity. We found that declining insulin sensitivity was associated with 5 year fatal or non-fatal CVD events, but not with all-cause mortality. The relationship between HOMA-%S and CVD events was largely explained by HDL, which significantly attenuated the association between HOMA-%S and CVD. Furthermore, only FPG significantly improved the prediction of CVD beyond that achieved by HDL, which significantly attenuated the association between HOMA-%S and CVD.

The question of whether insulin resistance directly leads to CVD or whether it has an indirect deleterious effect via other metabolic abnormalities is subject to debate. Findings from studies using a direct measurement of insulin sensitivity are limited. Although decreasing insulin sensitivity has been shown to be independently associated with an increased risk of CVD [9, 10], one of the studies only

### Table 2 Unadjusted and sex-adjusted risk of fatal or non-fatal CVD events according to quintiles of HOMA-%S in individuals without diagnosed diabetes (n=6,942): the AusDiab study

<table>
<thead>
<tr>
<th>Variables</th>
<th>Values per quintiles of HOMA-%S</th>
<th>p value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOMA-%S</td>
<td>48.6–37.2</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CVD events n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk in HR (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Adjusted for</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+FPG&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+2hPG&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+HbA&lt;sub&gt;1&lt;/sub&gt;&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+history of CVD</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+hypertension</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+SBP and DBP</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+lipid-lowering therapy and TC</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+triacylglycerol</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+non-HDL</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+HDL</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+WHR</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+waist circumference</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Age+sex+BMI</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Increasing quintiles of HOMA-%S represent decreasing insulin sensitivity

<sup>b</sup> Total CVD events: 225 (3.2)

<sup>c</sup> FPG was modelled as a linear spline with a knot at 5.1 mmol/l; HbA<sub>1</sub>c and 2hPG modelled as linear terms

<sup>d</sup> Models based on 6,933 participants with non-missing 2hPG values. Quintiles based on this sub-cohort

* <i>p</i> < 0.05

DPB, diastolic BP; SBP, systolic BP; TC, total cholesterol

1.1 (0.7–1.9) and 1.7 (1.1–2.9) (<i>p</i> < 0.01 for trend) after adjusting for age and sex. For individuals with a self-reported history of myocardial infarction or stroke at baseline (n=352), the corresponding HRs (95% CI) were 2.5 (0.9–7.2), 3.3 (1.2–9.3), 3.5 (1.3–9.7), 2.6 (0.9–7.6) (<i>p</i> = 0.06 for trend). Results were essentially unchanged when we repeated these analyses excluding people with newly diagnosed diabetes or replacing HOMA-%S with fasting insulin. Adding education level or physical activity did not alter the association between HOMA-%S and CVD (data not shown).

### Discussion

In this population-based prospective study of men and women we examined the relationship between HOMA-%S and both CVD and all-cause mortality, after accounting for a broad range of CVD risk factors, including previous history of CVD, smoking, hypertension, total cholesterol, lipid-lowering medication use, dyslipidaemia and obesity. We found that declining insulin sensitivity was associated with 5 year fatal or non-fatal CVD events, but not with all-cause mortality. The relationship between HOMA-%S and CVD events was largely explained by HDL, which significantly attenuated the association between HOMA-%S and CVD. Furthermore, only FPG significantly improved the prediction of CVD beyond that achieved by HOMA-%S and other CVD risk factors. There were no significant interactions between HOMA-%S and age, sex, glucose tolerance categories, history of CVD or obesity.

The question of whether insulin resistance directly leads to CVD or whether it has an indirect deleterious effect via other metabolic abnormalities is subject to debate. Findings from studies using a direct measurement of insulin sensitivity are limited. Although decreasing insulin sensitivity has been shown to be independently associated with an increased risk of CVD [9, 10], one of the studies only
used a surrogate CVD outcome (carotid artery intima–media thickness) and evaluated insulin resistance with an intravenous glucose tolerance test \[9\], while the other study (using the insulin clamp) only involved older men \[10\]. Several prospective studies using surrogate measures of insulin resistance have shown that the metabolic syndrome significantly attenuates the relationship between HOMA-IR and CVD \[22–24\], supporting the notion of an indirect link.

### Table 3

<table>
<thead>
<tr>
<th>Variables</th>
<th>Values per quintiles of HOMA-%S</th>
<th>( p ) value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>HOMA-%S</td>
<td>( &gt;74.6 )</td>
<td>74.6–59.3</td>
</tr>
<tr>
<td>CVD events, ( n ) (%)</td>
<td>26 (2.0)</td>
<td>30 (2.2)</td>
</tr>
<tr>
<td>Risk (HR [95% CI]) adjusted for age, sex, history of CVD and smoking</td>
<td>1.0</td>
<td>1.2 (0.7–2.0)</td>
</tr>
</tbody>
</table>

*a Increasing quintiles of HOMA-%S represent decreasing insulin sensitivity

*b Total CVD events: 225 (3.2)

*c History of previous CVD includes self-reported angina, myocardial infarction or stroke

*d Model does not include total cholesterol, as non-HDL and total cholesterol are highly correlated \( r=0.93 \)

*e \( p<0.05 \)

**LLT, lipid-lowering medication use; TC, total cholesterol; TG, triacylglycerol**

Several prospective studies using surrogate measures of insulin resistance have shown that the metabolic syndrome significantly attenuates the relationship between HOMA-IR and CVD \[22–24\], supporting the notion of an indirect link.

### Table 4

<table>
<thead>
<tr>
<th>HOMA-%S quintiles</th>
<th>Multivariate-adjusted ( b ) for FPG ( b, c )</th>
<th>Additionally adjusted for 2hPG ( b, d, e )</th>
<th>Additionally adjusted for HbA1c ( b, d, e )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI) Likelihood ratio test ( \chi^2 ) ( p ) value</td>
<td>HR (95% CI) Likelihood ratio test ( \chi^2 ) ( p ) value</td>
<td>HR (95% CI) Likelihood ratio test ( \chi^2 ) ( p ) value</td>
</tr>
<tr>
<td>( &gt;74.6 )</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>74.6–59.3</td>
<td>1.2 (0.7–2.0)</td>
<td>1.2 (0.7–2.0)</td>
<td>1.1 (0.7–1.9)</td>
</tr>
<tr>
<td>59.2–48.7</td>
<td>1.3 (0.8–2.1)</td>
<td>1.4 (0.9–2.2)</td>
<td>1.3 (0.8–2.1)</td>
</tr>
<tr>
<td>48.6–37.2</td>
<td>1.3 (0.8–2.2)</td>
<td>1.4 (0.9–2.3)</td>
<td>1.3 (0.8–2.1)</td>
</tr>
<tr>
<td>&lt;37.1</td>
<td>1.5 (0.9–2.4)</td>
<td>1.5 (0.9–2.5)</td>
<td>1.4 (0.9–2.4)</td>
</tr>
<tr>
<td>( p ) value for trend</td>
<td>0.12</td>
<td>0.11</td>
<td>0.15</td>
</tr>
</tbody>
</table>

*a Increasing quintiles of HOMA-%S represent decreasing insulin sensitivity

*b Adjusted for age, sex, history of CVD (angina, myocardial infarction or stroke), smoking (never smoked, ex-smoker, current smoker), hypertension (blood pressure \( \geq 140/90 \) mmHg or self-reported antihypertensive use), total cholesterol, HDL-cholesterol, lipid-lowering medication use and waist-to-hip ratio

*c FPG added to model as a linear spline with one knot at 5.1 mmol/l

*d Models based on 6,933 participants with non-missing 2hPG values. Quintiles based on this sub-cohort

*e 2hPG and HbA1c added to multivariate adjusted model as continuous variables
between insulin resistance and CVD through other metabolic pathways [34]. However, it is not possible to determine from these studies which metabolic factor had the strongest influence, as the metabolic syndrome was only considered in its entirety. Few epidemiological investigations have assessed the relative impact of several metabolic risk factors on the association between insulin resistance and CVD [19, 21], but those that did used HOMA-IR and not the updated HOMA-%S model. Our findings extend this previous work [19, 21], because we have specifically examined the individual impact of several metabolic risk factors and used HOMA-%S as the measure of insulin sensitivity.

The findings from our study seem to support the lipotoxicity hypothesis and suggest that HDL may be an important confounder of the association between insulin resistance and CVD. Although insulin resistance and dyslipidaemia (high triacylglycerol, low HDL) are characteristic of type 2 diabetes [35], individuals with diagnosed diabetes were excluded in this analysis, suggesting that insulin resistance and dyslipidaemia may also play a role in the development of CVD in the general population. The disappearance of the association between HOMA-%S and CVD after adjustment for HDL suggests that either: (1) HDL is the key risk factor (and that the univariate association between HOMA-%S and CVD is due to the links between insulin sensitivity and HDL levels); or (2) low HDL is a consequence of insulin resistance and that adjusting for it is potentially an over-adjustment. However, our data do not allow us to assess which of the above applies. It is also possible that other underlying factors are responsible for the development of insulin resistance and abnormal HDL metabolism. One theory suggests that obesity may be a common antecedent, as it leads to an increase in circulating NEFA, which in turn have a deleterious effect on insulin resistance and associated hepatic lipoprotein abnormalities, including a reduction in HDL [36]. Indeed, waist circumference has been shown to be more strongly associated with and to precede the development of metabolic abnormalities than insulin resistance measured by HOMA-%S [37]. However, it was not possible to evaluate this further in this study.

Nevertheless, other studies have shown HOMA-IR [19, 21] and hyperinsulinaemia [13, 25, 38] to be significantly associated with CVD, despite adjusting for HDL and other metabolic factors. However, all but two [25, 38] of these studies used a non-specific insulin assay which cross-reacts with proinsulin [13, 19, 21]. As proinsulin may be a better predictor of CVD than fasting insulin [10] or HOMA-IR [39], the association between true insulin and CVD may have been concealed in these previous studies. Moreover, the findings from the two studies that did use a specific insulin assay may not be generalisable to the general population as one was conducted in older women [25] and the other only included men and measured non-fasting insulin [38].

Many studies have reported on the CVD risks associated with non-diabetic hyperglycaemia and insulin resistance, but few have compared the relative associations between these conditions and CVD in the same study population, and results are inconsistent. Several studies [40–42], including a meta-analysis [13], have reported a significant association between hyperinsulinaemia and CVD events after adjusting for glucose. However, these associations may have been the result of residual confounding, as none adjusted for HDL or waist circumference, factors that are known to coexist with insulin resistance and also to increase the likelihood of CVD [7]. Furthermore, although some studies have found blood glucose to be a better predictor of CVD than hyperinsulinaemia [43] or HOMA-IR [24], others have not [25, 38]. However, the latter two studies were conducted in particular populations: older women [25] and middle-aged men [38]. In our study, prediction of CVD events significantly improved with the addition of FPG, but not HOMA-%S to models adjusted for age, sex and other CVD risk factors. This suggests that in the general population, FPG and other CVD risk factors, rather than HOMA-%S, may be the important targets for prevention of CVD.

Several limitations need to be considered when interpreting these results. First, as this is a large population-based study, it was not feasible to measure insulin sensitivity directly with an insulin clamp. Instead, insulin sensitivity was estimated with HOMA-%S, which is a relatively simplistic index of insulin sensitivity calculated from fasting plasma insulin and glucose levels. Consequently, the non-significant findings in this study may be attributable to the imprecision of HOMA-%S. Although HOMA-%S has been found to be significantly correlated \( r=0.88 \) with insulin sensitivity, this finding was only based on a small study using the minimal model [44]. Thus, further research using the insulin clamp is required to confirm our findings. Second, we were not able to account for the influence of intra-individual variation in HOMA-%S measurements, as they were based on only one measurement. However, findings from large datasets have shown that measurements using a single sample yield similar results to those from multiple samples [17]. Third, this study examined the risk of CVD and mortality over a 5 year period, which may not be long enough to detect a significant association, although several other studies have demonstrated that the relationship between insulin resistance (as estimated with hyperinsulinaemia) and CVD becomes weaker with time [45]. Finally, the generalisability of this study to the Australian population is limited by the estimated baseline response rate of 37%. Non-
English speaking Australians and people who completed less than 12 years of school were under-represented in AusDiab, so these findings may not be generalisable to these groups [26].

In conclusion, this prospective population-based study of men and women evaluated the association between HOMA-%S and CVD after adjusting for a wide range of CVD risk factors. It is also one of the few studies to use a specific insulin assay to measure serum insulin levels. We found FPG to be a better predictor of CVD than HOMA-%S. Over a 5 year period there was no association between HOMA-%S and all-cause mortality, and only a modest relationship between HOMA-%S and both fatal or non-fatal CVD events, mainly explained by the clustering of other risk factors, in particular HDL. These findings are consistent with the notion that insulin resistance plays an indirect role in the development of CVD, although the question of whether insulin resistance is the cause of other metabolic abnormalities remains debatable and requires further research.

Acknowledgements E. L. M. Barr is supported by a National Health and Medical Research Council (NHMRC; 379305)/National Heart Foundation Australia (PP 05M 2346) joint postgraduate scholarship. A. J. Cameron is supported by Postgraduate Research Scholarship (PP 04M 1794) from the National Heart Foundation of Australia. The AusDiab study, co-coordinated by the Baker Heart and Diabetes Research Institute, gratefully acknowledges the generous support given by: National Health and Medical Research Council (NHMRC grant 233200), National Heart Foundation Australia (Research Grant-in-Aid RES17-01 2005) for the collection of and adjudication of medical records and in-kind support from the Australian Institute of Health and Welfare, who provided the mortality data. In addition, we are most grateful to the following for their support: The Commonwealth Department of Health and Aged Care, Abbott Australasia, Alphapharm, AstraZeneca, Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Australia), GlaxoSmithKline, Janssen–Cilag (Australia), Merck Lapha, Merck Sharp & Dohme (Australia), Novartis Pharmaceutical (Australia), Novo Nordisk Pharmaceutical, Pharmacia and Upjohn, Pfizer, Roche Diagnostics, Sanofi Synthelabo (Australia), Servier Laboratories (Australia), Bio-Rad Laboratories, HITECH Pathology, the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services and Victorian Department of Human Services, and Health Department of Western Australia. For their invaluable contribution to the set-up and field activities of AusDiab, we are enormously grateful to: A. Allman, B. Atkins, S. Bennett, A. Bonney, S. Chadban, M. de Courten, M. Dalton, D. Dunstan, T. Dwyer, H. Jahangir, D. Jolley, D. McCarty, A. Meehan, N. Meinig, S. Murray, K. O’Dea, K. Polkinghorne, P. Phillips, C. Reid, A. Stewart, R. Tapp, H. Taylor, T. Whalen and F. Wilson. A special acknowledgement also goes to S. Murray, G. Filby and medical records staff, who helped in the collection of medical record information. Finally, we thank the AusDiab participants for volunteering their time to participate in the study.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

References